U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2.2C4H6O6
Molecular Weight 462.4052
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICOTINE BITARTRATE ANHYDROUS

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCC[C@H]1C2=CN=CC=C2

InChI

InChIKey=RFEJUZJILGIRHQ-OMDKHLBYSA-N
InChI=1S/C10H14N2.2C4H6O6/c1-12-7-3-5-10(12)9-4-2-6-11-8-9;2*5-1(3(7)8)2(6)4(9)10/h2,4,6,8,10H,3,5,7H2,1H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t10-;2*1-,2-/m011/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C10H14N2
Molecular Weight 162.2316
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Sources: www.inchem.org/documents/pims/chemical/nicotine.htm
Curator's Comment: description was created based on several sources, including https://cancercontrol.cancer.gov/brp/tcrb/monographs/1/index.html https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/

Nicotine is a natural alkaloid obtained from the dried leaves and stems of the nightshade family of pants, such as Nicotiana tabacum and Nicotiana rustica, where it occurs in concentrations of 0.5-8%. Cigarette tobacco varies in its nicotine content, but common blends contain 15-25 mg per cigarette, with a current trend towards lower levels. Nicotine is highly addictive substance, it exhibits a stimulant effect when adsorbed at 2 mg. Administration of higher doses could be harmful. Action of nicotine is mediated by nicotinic cholinergic receptors. Nicotine binds to the interface between two subunits of the receptors, opens the channel and allows the entry of sodium or calcium. The principal mediator of nicotine dependence is α4β2 nicotine receptor.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NICORETTE

Approved Use

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking

Launch Date

1984
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12 ng/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
6 ng × h/mL
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 min
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
95%
1 mg single, nasal
dose: 1 mg
route of administration: Nasal
experiment type: SINGLE
co-administered:
NICOTINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Bradycardia...
AEs leading to
discontinuation/dose reduction:
Bradycardia (1 patient)
Sources:
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Disc. AE: Allergic dermatitis...
AEs leading to
discontinuation/dose reduction:
Allergic dermatitis (1 patient)
Sources:
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Hypersensitivity, Nausea...
AEs leading to
discontinuation/dose reduction:
Hypersensitivity (1 patient)
Nausea (1 patient)
Sources:
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Disc. AE: Depression, Nausea...
AEs leading to
discontinuation/dose reduction:
Depression (1 patient)
Nausea (grade 2-3, 2 patients)
Sources:
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Death...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 1 patient)
Sources:
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Other AEs: Nausea...
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
Disc. AE
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Allergic dermatitis 1 patient
Disc. AE
4 mg single, oral
Studied dose
Dose: 4 mg
Route: oral
Route: single
Dose: 4 mg
Sources:
healthy, 19 - 49 years
n = 44
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 49 years
Sex: M+F
Population Size: 44
Sources:
Hypersensitivity 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea 1 patient
Disc. AE
6 mg 1 times / hour steady, oral
Highest studied dose
Dose: 6 mg, 1 times / hour
Route: oral
Route: steady
Dose: 6 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Depression 1 patient
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Nausea grade 2-3, 2 patients
Disc. AE
8 mg 1 times / hour steady, oral
Highest studied dose
Dose: 8 mg, 1 times / hour
Route: oral
Route: steady
Dose: 8 mg, 1 times / hour
Sources:
healthy, 19 - 50 years
n = 50
Health Status: healthy
Condition: adult smokers
Age Group: 19 - 50 years
Sex: M+F
Population Size: 50
Sources:
Death grade 5, 1 patient
Disc. AE
111 mg single, transdermal
Overdose
Dose: 111 mg
Route: transdermal
Route: single
Dose: 111 mg
Sources:
healthy, 41 years
n = 1
Health Status: healthy
Condition: adult smoker
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
Nausea
84 mg 1 times / day steady, transdermal
Highest studied dose
Dose: 84 mg, 1 times / day
Route: transdermal
Route: steady
Dose: 84 mg, 1 times / day
Sources:
healthy, adult
n = 36
Health Status: healthy
Condition: adult smokers
Age Group: adult
Sex: unknown
Population Size: 36
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Modulation of phosphatidylinositol turnover on central nicotinic receptors.
1997 Jul
[Treatment outcome in tobacco dependence after nicotine replacement therapy and group therapy].
1999
Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line.
1999 Apr 17
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.
1999 Feb 5
Pharmacological characterization of nicotine's interaction with cocaine and cocaine analogs.
1999 Jun
Chronic nicotine pretreatment protects the blood-brain barrier against nicotine-induced seizures in the rat.
1999 Sep
Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
2000 Apr
Chick optic lobe contains a developmentally regulated alpha2alpha5beta2 nicotinic receptor subtype.
2000 Aug
Dermal exposure to pesticides modifies antioxidant enzymes in tissues of rats.
2000 Jul
Antioxidant effect of onion oil (Allium cepa. Linn) on the damages induced by nicotine in rats as compared to alpha-tocopherol.
2000 Jul 27
Nicotine switches the form of H(2)O(2)-induced cell death from apoptosis to necrosis in U937 cells.
2000 Jun 1
Neurobiological mechanisms by which nicotine mediates different types of anxiety.
2000 Mar 30
Abstinence effects and reactivity to nicotine during 11 days of smoking deprivation.
2000 May
Kynurenic acid does not protect against nicotine-induced seizures in mice.
2000 Nov-Dec
Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior.
2000 Oct
Prenatal nicotine exposure is associated with an increase in [125I]epibatidine binding in discrete cortical regions in rats.
2000 Oct
Contributory role for nornicotine in nicotine neuropharmacology: nornicotine-evoked [3H]dopamine overflow from rat nucleus accumbens slices.
2001 Dec 15
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats.
2001 Jan
Nornicotine, a nicotine metabolite and tobacco alkaloid: desensitization of nicotinic receptor-stimulated dopamine release from rat striatum.
2001 Sep 28
Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung.
2002 Apr 8
Absence of alpha7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures.
2002 Jan 31
Enhancement of cocaine-seeking behavior by repeated nicotine exposure in rats.
2002 Jul
Increased sensitivity to nicotine-induced seizures in mice expressing the L250T alpha 7 nicotinic acetylcholine receptor mutation.
2002 Mar
N-glucuronidation of nicotine and cotinine in human: formation of cotinine glucuronide in liver microsomes and lack of catalysis by 10 examined UDP-glucuronosyltransferases.
2002 Sep
Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes.
2003 Jan 1
Nicotinic acetylcholine receptors and the regulation of neuronal signalling.
2004 Jun
Patents

Sample Use Guides

Reduces withdrawal symptoms, including nicotine craving associated with quitting smoking, nicotine is available as a chewing gum, and is administered according to a schedule at doses 2-4 mg once every 2-4 hours. Nicotine is also available as a transdermal patch.
Route of Administration: Other
Functional activity of nicotine against hα4β2 nicotinic receptors was evaluated using the 86Rb+ ion flux assay in SH-EP1 cells, expressing hα4β2. The 86Rb+ efflux was measured using the “flip-plate” technique. Nicotine activated 86Rb+ efflux with EC50 of 290 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:18:00 GMT 2023
Edited
by admin
on Fri Dec 15 16:18:00 GMT 2023
Record UNII
7892ZN5G41
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICOTINE BITARTRATE ANHYDROUS
Common Name English
PYRIDINE, 3-(1-METHYL-2-PYRROLIDINYL)-, (S)-, (R-(R*,R*))-2,3- DIHYDROXYBUTANEDIOATE (2:1)
Common Name English
NICOTINE TARTRATE [HSDB]
Common Name English
NICOTINE TARTRATE
HSDB  
Systematic Name English
NICOTINE HYDROGEN TARTRATE
Systematic Name English
NICOTINE BITARTRATE [MI]
Common Name English
PYRIDINE, 3-((2S)-1-METHYL-2-PYRROLIDINYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:2)
Systematic Name English
NSC-97238
Code English
NICOTINE HYDROGEN-L-TARTRATE
Common Name English
NICOTINE L-(+)-TARTRATE (1:2)
Systematic Name English
NICOTINE TARTRATE (1:2)
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID401017270
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
FDA UNII
7892ZN5G41
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-607-2
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
PUBCHEM
11957628
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
MERCK INDEX
m7879
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY Merck Index
HSDB
806
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
RXCUI
1306106
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY RxNorm
CAS
65-31-6
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
EVMPD
SUB22391
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
SMS_ID
100000086058
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
NSC
97238
Created by admin on Fri Dec 15 16:18:00 GMT 2023 , Edited by admin on Fri Dec 15 16:18:00 GMT 2023
PRIMARY
Related Record Type Details
SUBSTANCE->BASIS OF STRENGTH
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY